ArticleMikrochimica acta2026
Immunochromatographic SERS sensor-deep learning combined strategy for intelligent diagnosis of chronic kidney disease.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
A combined "immunochromatographic surface-enhanced Raman scattering (SERS) sensor-deep learning" detection strategy is proposed. Specifically, we first prepared an immunochromatographic SERS sensor with excellent surface enhancement capability for the specific recognition of neutrophil gelatinase-associated lipocalin (NGAL) molecules in serum, significantly enhancing the detection sensitivity of the target molecule. Subsequently, we integrated deep learning algorithms to perform preprocessing, feature extraction, and pattern recognition analysis on complex SERS spectral signals, overcoming the limitations of traditional algorithms in handling high-dimensional nonlinear data. This approach enables rapid, sensitive, and highly specific detection of NGAL. The platform achieves a detection limit as low as 0.1059 ng/mL with a broad linear detection range. For clinical validation, serum samples from 14 volunteers were analyzed. Six deep learning models were employed to classify the acquired clinical spectral data, with the Residual Network (ResNet) model achieving a classification accuracy of 98.81%, a loss value of only 0.0877, and an area under the receiver operating characteristic curve (AUC) of 99.97%. In addition, in the analysis of new samples, the classification and prediction of data from patients and normal individuals were successfully achieved. The proposed "immunoassay surface-enhanced Raman scattering sensor - deep learning" combined detection strategy has demonstrated extraordinary potential in the rapid, sensitive and specific detection of NGAL, providing crucial technical support for the intelligent discrimination of chronic kidney disease.
Indexed as
Identifiers
41634249What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.